2024
In-Hospital Outcomes and 30-Day Readmission Rate After Transcatheter and Surgical Aortic Valve Replacement in Liver Cirrhosis: A Contemporary Propensity-Matched Analysis
Aggarwal A, Jang S, Vardhan S, Webber F, Alam M, Vardhan M, Lancaster G, Ahmad Y, Vora A, Zarich S, Inglessis-Azuaje I, Elmariah S, Forrest J, Davila C. In-Hospital Outcomes and 30-Day Readmission Rate After Transcatheter and Surgical Aortic Valve Replacement in Liver Cirrhosis: A Contemporary Propensity-Matched Analysis. Structural Heart 2024, 100327. DOI: 10.1016/j.shj.2024.100327.Peer-Reviewed Original ResearchSurgical aortic valve replacementTranscatheter aortic valve replacementAortic valve replacementTranscatheter aortic valve replacement groupValve replacementIn-hospital mortalityHepatorenal syndromeReadmission ratesCardiogenic shockLiver cirrhosisVascular complicationsIn-hospitalOutcomes of transcatheter aortic valve replacementSurgical risk prediction modelsSurgical aortic valve replacement groupAssociated with significantly lower ratesRates of in-hospital mortalityLimited contemporary dataIn-hospital outcomesSignificantly lower ratesNationwide Readmissions DatabaseCardiac surgeryPeriprocedural morbidityTherapeutic optionsClinical characteristics
2023
TCT-67 Comparison of In-Hospital Outcomes and 30-Day Readmission Rates Between Patients Who Underwent TAVR Versus SAVR for Aortic Stenosis in Liver Cirrhosis: A Propensity-Matched Analysis
Aggarwal A, Jang S, Vardhan S, Webber F, Lancaster G, Zarich S, Vora A, Elmariah S, Davila C. TCT-67 Comparison of In-Hospital Outcomes and 30-Day Readmission Rates Between Patients Who Underwent TAVR Versus SAVR for Aortic Stenosis in Liver Cirrhosis: A Propensity-Matched Analysis. Journal Of The American College Of Cardiology 2023, 82: b27. DOI: 10.1016/j.jacc.2023.09.072.Peer-Reviewed Original ResearchCOMPARISON OF IN - HOSPITAL OUTCOMES AND THIRTY - DAY READMISSION RATES BETWEEN PATIENTS WHO UNDERWENT TAVR VERSUS SAVR FOR AORTIC STENOSIS IN LIVER CIRRHOSIS: RESULTS FROM NATIONWIDE READMISSIONS DATABASE
Aggarwal A, Jang S, Webber F, Shkolnik E, Pinto E, Lancaster G, Zarich S. COMPARISON OF IN - HOSPITAL OUTCOMES AND THIRTY - DAY READMISSION RATES BETWEEN PATIENTS WHO UNDERWENT TAVR VERSUS SAVR FOR AORTIC STENOSIS IN LIVER CIRRHOSIS: RESULTS FROM NATIONWIDE READMISSIONS DATABASE. Journal Of The American College Of Cardiology 2023, 81: 1020. DOI: 10.1016/s0735-1097(23)01464-x.Peer-Reviewed Original Research
2011
Fatal Rhabdomyolysis in a Patient with Liver Cirrhosis after Switching from Simvastatin to Fluvastatin
Baek S, Jang S, Park S, Ok T, Leem J, Lee H, Park S, Kim T. Fatal Rhabdomyolysis in a Patient with Liver Cirrhosis after Switching from Simvastatin to Fluvastatin. Journal Of Korean Medical Science 2011, 26: 1634-1637. PMID: 22148003, PMCID: PMC3230026, DOI: 10.3346/jkms.2011.26.12.1634.Peer-Reviewed Original ResearchConceptsFatal rhabdomyolysisLiver cirrhosisContinuous renal replacement therapyAcute renal failureRenal replacement therapyCoronary artery diseaseHMG-CoA reductase inhibitorsSerum creatine kinaseAsymptomatic elevationIntravenous furosemideRenal failureUrine alkalizationArtery diseaseHepatic failureReplacement therapyMassive hydrationRhabdomyolysisPatientsCirrhosisReductase inhibitorsCreatine kinaseAdverse effectsSimvastatinFluvastatinCandesartan